Elsevier

Schizophrenia Research

Volume 202, December 2018, Pages 212-216
Schizophrenia Research

Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis

https://doi.org/10.1016/j.schres.2018.06.029Get rights and content

Abstract

This study evaluated the ability to flexibly shift cognitive set and to consistently maintain a new response preference using the Penn Conditional Exclusion Test (PCET). The relationship of performance errors with catechol-O-methyltransferase (COMT) rs4680 (Val158Met) genotype (Met carriers vs. Val homozygotes) on test performance before and after antipsychotic treatment in 32 first episode psychosis (FEP) patients was examined. After treatment, patients demonstrated a mixture of beneficial and adverse cognitive outcomes that varied in relation to COMT genotype. Met carriers showed decreased perseverative and regressive errors, reflecting improved cognitive flexibility and enhanced stability of behavioral preferences, respectively. In contrast, Val homozygotes exhibited an increase in regressive errors after treatment. These findings suggest that Val homozygotes may be vulnerable to adverse effects of antipsychotic medication on cognitive processes that maintain consistent adaptive response preferences, an ability linked to the striatum in rodent models.

Introduction

The ability to flexibly adjust behavior to changing environmental demands (cognitive flexibility), and to maintain newly learned behavioral preferences without regressing to previous, and no longer adaptive, response preferences (cognitive stability) form important complementary components of executive function (Diamond, 2013). Patients with schizophrenia and affective disorders have well-established disturbances in cognitive flexibility and stability evident in many studies using the Wisconsin Card Sorting Test (WCST) (Heaton et al., 1994; Merriam et al., 1999). Similar deficits have been reported on a computerized analog of the WCST, the Penn Conditional Exclusion Test (PCET) (Hill et al., 2015). Utilizing translational models of cognition evaluating discrete components of behavioral set shifting mediated by different brain regions may improve the sensitivity of set-shifting tasks for understanding cognitive deficits in psychotic disorders and for evaluating treatment outcomes and genetic associations.

Research using animal models has indicated a critical role for the interaction between dopaminergic activity in the prefrontal cortex and striatum in set-shifting. Specifically, cognitive flexibility is impaired by a combination of decreased prefrontal dopamine (DA) and elevated striatal DA, while cognitive stability is impaired in the context of increased prefrontal DA and decreased striatal dopaminergic activity (Amodeo et al., 2014; Ragozzino et al., 2002; Roberts et al., 1994).

Animal studies investigating the role of D1 dopamine receptors in the PFC have focused on delayed response tasks, which require online maintenance of a previously presented stimulus. Striatal dopamine is thought to be important for flexibility and updating goal representations when new information is pertinent (Cools and D'Esposito, 2011). Research using non-human primates revealed that destruction of dopamine neurons in the PFC resulted in enhanced distractibility (poor cognitive stability), while dopamine depletion in the striatum resulted in reduced distractibility (poor cognitive flexibility) (Crofts et al., 2001). These opposing effects of PFC and striatal lesions on dopamine systems highlight the possible competition between the PFC and the striatum, and suggest that a dynamic balance between stabilization and flexible updating depends on balanced dopamine transmission within the PFC and striatum respectively. This functional opposition between flexibility and stability is consistent with the model of neurochemical reciprocity between dopamine in the PFC and the striatum in which variability in PFC dopaminergic activity leads to corresponding changes in striatal dopamine activity (Cools and D'Esposito, 2011; Tunbridge et al., 2006).

Catechol-O-methyltransferase (COMT) enzyme activity is a significant regulator of synaptic DA in the prefrontal cortex (Chen et al., 2004). The rs4680 A>G polymorphism in COMT results in a valine to methionine amino acid change which decreases the in vivo stability of the COMT enzyme, reducing DA catabolism, thus increasing synaptic DA. COMT activity in Val/Val homozygotes is approximately 38% higher than Met/Met homozygotes and 29% higher than Val/Met heterozygotes in the dorsolateral prefrontal cortex (DLPFC) (Chen et al., 2004). Thus, COMT genotype may be an important factor in mediating cognitive flexibility and stability supported by dopamine activity in the PFC and striatum respectively. Further, the Met allele is hypothesized to be associated with more tonic than phasic dopamine release in subcortical regions, and higher dopamine concentrations in the cortex that leads to greater cognitive stability and more limited cognitive flexibility (Bilder et al., 2004). In contrast, the Val allele is believed to be associated with more phasic dopamine activity in subcortical regions and lower dopamine concentrations in the cortex, leading to greater cognitive flexibility and reduced behavioral stability, particularly in Val homozygotes (Bilder et al., 2004).

In this study we examined the role of a well characterized genetic polymorphism in the COMT gene in mediating cognitive antipsychotic treatment effects in first episode psychosis (FEP). We considered catechol-O-methyltransferase (COMT) to be a potentially important baseline consideration in a pharmacogenomic context because Met carriers and Val homozygotes respond differently to antipsychotic therapy (Huang et al., 2016). In previous studies, Met carriers have demonstrated improved performance on the N-back task compared to Val homozygotes following antipsychotic pharmacotherapy (Bertolino et al., 2004; Weickert et al., 2004). Because COMT modulates dopaminergic systems differently in the PFC and striatum due to limited DA transporter (DAT) expression in PFC (Cools and D'Esposito, 2011; Tunbridge et al., 2006), evaluating the relation between COMT genotype and components of set-shifting that are differentially dependent on prefrontal and striatal function before and after treatment with antipsychotics may shed light on mechanisms underlying variable cognitive outcomes following antipsychotic therapy.

Section snippets

Participants

FEP participants (54.8% schizophrenia spectrum disorder, 29.0% bipolar disorder with psychosis, 12.9% major depressive disorder with psychosis, 3.2% psychotic disorder NOS) were evaluated, performed cognitive testing and then treated at the University of Illinois at Chicago (UIC). Participants were considered first episode if this were their first hospitalization for acute psychotic symptoms and had limited prior exposure to antipsychotic medication. Individuals presenting to emergency rooms

Baseline comparison of patients and controls

Group performance on the PCET before and after treatment is summarized in Table 2. For perseverative errors the Poisson regression indicated significant main effects of group [χ2 = 7.24, p = .007] and genotype [χ2 = 14.50, p < .001] as well as a significant group by genotype interaction effect [χ2 = 16.29, p < .001]. Analysis of regressive errors revealed significant main effects of group [χ2 = 3.99, p = .046] and genotype [χ2 = 8.74, p = .003], as well as a significant group by genotype

Discussion

This study demonstrated differential cognitive change after acute antipsychotic therapy in untreated first episode patients with psychotic disorders based on COMT genotype. Met carriers with FEP showed cognitive improvement after antipsychotic treatment characterized by a significant reduction of both perseverative and regressive errors. These findings indicate enhanced cognitive flexibility and stability for Met carriers, respectively, following antipsychotic treatment. These observations

Acknowledgements

We thank Drs. Ovidio DeLeon, Margret Harris, Hugo Solari, Peter Weiden, and the clinical core staff of the UIC Center for Cognitive Medicine for their contributions to diagnostic and psychopathological assessments. We also thank Shitalben Patel for her contributions to the genotyping portions of this work. This study was supported in part by NARSAD, NIMH Grants MH077862, MH083888, MH062134, MH080066, and MH072767 and American College of Clinical Pharmacy.

Conflicts of interest

Dr. Sweeney has received support from Takeda. The other authors have no conflicts of interest at this time.

Role of the funding source

This project was supported by the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) and the National Institutes of Health (NIMH: MH077862, MH062134, MH080066, and MH072767).

Contributors

Courtney Nelson is the lead author and was responsible for data analysis and manuscript preparation. Dr. Hill is the corresponding author and he was involved in all aspects of the report. Hayley Amsbaugh was involved in writing portions of the report. Dr. Reilly was responsible for data management and supervision of clinical and cognitive assessments. Dr. Bishop was responsible for handling genetic data and contributed to writing the report. Drs. Rosen and Marvin were involved in recruitment

References (28)

  • D.A. Amodeo et al.

    Risperidone and the 5-HT2A receptor antagonist, M100907 improve probabilistic reversal learning in BTBR T+ tf/J mice

    Autism Res.

    (2014)
  • A. Bertolino et al.

    Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia

    Am. J. Psychiatry

    (2004)
  • R.M. Bilder et al.

    The catechol-o-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes

    Neuropsychopharmacology

    (2004)
  • R. Cools et al.

    Inverted u-shaped dopamine actions on human working memory and cognitive control

    Biol. Psychiatry

    (2011)
  • Cited by (6)

    • Catechol-O-methyltransferase genotype differentially contributes to the flexibility and stability of cognitive sets in patients with psychotic disorders and their first-degree relatives

      2020, Schizophrenia Research
      Citation Excerpt :

      Notably, although Rosa et al. (2010) and others have found support for the role of the Met allele in promoting maintenance, evidence for the Val allele promoting flexibility is far less consistent. Substantial heterogeneity in operationalizing and isolating cognitive flexibility and stability (over the distinct construct of cognitive control) may partially contribute to this inconsistency; however, it is more likely due to the complexity of dopaminergic interactions with frontostriatal functions and cognition compared to the relative simplicity of the model being evaluated (Bilder et al., 2004; Nelson et al., 2018; Nolan et al., 2004; Rosa et al., 2010). Regardless further research is needed to both refine the tonic-phasic model as well as further clarify any unique impact of the Val allele.

    • Pharmacogenomics of bipolar disorder

      2020, Neurobiology of Bipolar Disorder: Road to Novel Therapeutics
    View full text